contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-mendus-year-end-report-for-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Mendus utvecklar immunterapier mot cancer med fokus på att förebygga tumöråterfall, ansvarigt för majoriteten av cancerrelaterade dödsfall globalt. Indikationerna omfattar akut myeloid leukemi, äggstockscancer och mjukdelssarkom. Företaget brukade heta Immunicum och omdöptes till Mendus efter sammanslagningen med det nederländska privata företaget DCprime 2021. Mendus har sitt huvudkontor i Stockholm och sin operativa verksamhet i Leiden i Nederländerna.

Del 2 av artikelserien! Sannolikheter för framgång inom läkemedelsutveckling Den andra delen av vår artikelserie som fokuserar på grunderna i att investera i Life Science-företag handlar om sannolikheten för framgångsrik läkemedelsutveckling. Läkemedelsutvecklingsföretag undersöker vanligtvis säkerhet, tolerabilitet och effektivitet hos en läkemedelskandidat i tre kliniska faser…                   Inderes              Probabilities of success in drug development - Inderes    The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Vi inleder nu en artikelserie med fokus på grunderna i att investera i Life Science-bolag. Denna första del av serien beskriver de kliniska faserna i läkemedelsutvecklingen som de flesta läkemedelsutvecklingsföretag måste gå igenom.                  Inderes              Clinical phases of drug development - Inderes    We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they...

Ny uppdaterad analys efter Q2 rapport i fredags från Mendus!                   Inderes              Mendus Q2'24: Ilixadencel to return to the clinical arena - Inderes    For Mendus, Q2'24 marked the start of the pivotal CADENCE trial in acute myeloid leukemia (AML). The company also announced plans to restart clinical development of ilixadencel in soft tissue sarcomas.

Mendus har släppt sin rapport för det andra kvartalet. I en intervju sammanfattar VD Erik Manting vad som hände under det andra kvartalet, presenterar de viktigaste framstegen i CADENCE-studien och berättar om den nya studien med läkemedlet Ilixadencel.                    Inderes              Mendus Q2´24: The CADENCE trial has started - Inderes    Time: 2024-08-23 14:42 Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with...

Mendus började rekrytera patienter till CADENCE-studien under det andra kvartalet 2024. Mendus Q2’24 resultatförhandsvisning: Mendus will release its Q2 results on Friday, August 23, at 08:00 am CEST. The live Q2 presentation and business update can be viewed here.                   Inderes              Mendus Q2'24 earnings preview: Patient recruitment started for CADENCE trial ...    Mendus will release its Q2 results on Friday, August 23, at 08:00 am CEST. The live Q2 presentation and business update can be viewed here.

Read the latest report that was published today:                   Inderes              AML development on track - Inderes    Q1 Ethics Committee approval cleared the way for Mendus and partner ALLG to start patient recruitment for the CADENCE trial in acute myeloid leukemia (AML) in Q2’24. In parallel, Mendus is building readiness for a pivotal-stage trial in AML supported...

CEO Erik Manting comments on the company’s Q1 and upcoming events in @antti.siltanen 's interview!                    Inderes              Mendus Q1’24: Progress with main partnerships - Inderes    Mendus made progress with main partnerships in Q1. CEO Erik Manting comments on the topic and other main events of Q1 as well as upcoming events in this interview.

Mendus

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2024 on Thursday 13 February at 08.00 CET. The company will host a live presentation and business update on the same ...

<div class="mfn-preamble"><p><strong>Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2024 on Thursday 13 February at 08.00 CET. The company will host a live presentation and business update on the same day at 08.30 CET. The presentation will be held in English and includes a Q&amp;A session</strong></p></div><div class="mfn-body"><p>Date and time: Thursday 13 February at 08.30 CET</p><p>The presentation can be followed via:<br><a rel="noopener" href="https://mendus.events.inderes.com/q4-report-2024/register">https://mendus.events.inderes.com/q4-report-2024/register</a></p><p>If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.<br><a rel="noopener" href="https://conference.inderes.com/teleconference/?id=5004794">https://conference.inderes.com/teleconference/?id=5004794</a></p></div><div class="mfn-footer mfn-contacts mfn-17d81f918f4c"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Erik Manting<br>Chief Executive Officer<br>E-mail: <a rel="noopener" href="mailto:ir@mendus.com">ir@mendus.com</a></p></div><div class="mfn-footer mfn-about mfn-868be8723f72"><p><strong class="mfn-heading-1">About Mendus AB (publ)</strong></p><p>Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <a rel="noopener" href="https://www.mendus.com/">https://www.mendus.com/</a> </p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/ca6a49f9-a3ab-4348-8566-0be0d4b80220/invitation-to-presentation-of-mendus-year-end-report-for-2024.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Mendus’ year-end report for 2024</a></p></div>